Date Filed | Type | Description |
08/14/2023 |
SC 13D/A
| Western Standard LLC reports a 13.9% stake in Merrimack Pharmaceuticals, Inc. |
08/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/04/2023 |
8-K
| Quarterly results |
05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
02/14/2023 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 0% stake in Merrimack Pharmaceuticals, Inc. |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
12/05/2022 |
8-K
| Quarterly results |
11/30/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
11/09/2022 |
8-K
| Quarterly results |
11/03/2022 |
8-K
| Quarterly results |
11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
08/04/2022 |
8-K
| Quarterly results |
08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/04/2022 |
SC 13G
| Point72 Asset Management, L.P. reports a 6.7% stake in Merrimack Pharmaceuticals, Inc. |
08/03/2022 |
8-K
| Quarterly results |
06/09/2022 |
8-K
| Quarterly results |
05/05/2022 |
8-K
| Quarterly results |
05/05/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
04/27/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
04/27/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/09/2022 |
8-K
| Quarterly results |
03/09/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
02/14/2022 |
SC 13G/A
| 22NW, LP reports a 9.3% stake in Merrimack Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 4.3% stake in Merrimack Pharmaceuticals, Inc. |
11/04/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
08/05/2021 |
8-K
| Quarterly results |
08/05/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
08/05/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
|